دورية أكاديمية
Analysis of somatic mutations in the JAK2, CALR, MPL and ASXL1 genes and evaluation of their impact on the survival of patients with myelofibrosis
| العنوان: | Analysis of somatic mutations in the JAK2, CALR, MPL and ASXL1 genes and evaluation of their impact on the survival of patients with myelofibrosis |
|---|---|
| المؤلفون: | T. N. Subbotina, I. E. Maslyukova, K. S. Semashchenko, G. A. Khodos, D. V. Kurochkin, A. A. Shalyova, M. A. Mikhalev, E. V. Vasiliev, M. G. Osadchaya, E. A. Dunaeva, A. S. Esman, K. O. Mironov |
| المصدر: | Онкогематология, Vol 18, Iss 1, Pp 63-75 (2023) |
| بيانات النشر: | ABV-press, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs |
| مصطلحات موضوعية: | asxl1, jak2, calr, mpl, myelofibrosis, overall survival, Diseases of the blood and blood-forming organs, RC633-647.5 |
| الوصف: | Background. The development of myelofibrosis (MF) is driven by complex molecular genetic events that include driver somatic mutations responsible for the constitutive activation of the JAK/STAT signaling pathway (JAK2, CALR, and MPL), additional mutations affecting epigenetic regulators (TET2, ASXL1, IDH1/2, etc.) and RNA splicing (SRSF2, U2AF1, SF3B1, etc.), as well as genetic aberrations that contribute to genomic instability and disease progression.Aim. To analyze driver (JAK2, CALR, MPL) and prognostic (ASXL1) somatic mutations in patients with MF and evaluate their impact on survival.Materials and methods. The study included 29 patients diagnosed with MF, selected by hematologists from the City Clinical Hospital No. 7 and Regional Clinical Hospital (Krasnoyarsk).Results. 26 (89.6 %) out of 29 examined patients had some driver mutations in JAK2, CALR, MPL genes. The p.V617F mutation in the JAK2 gene was found in 20 (68.9 %) patients. Mutations in the CALR gene were detected in 4 (13.8 %) patients, mutations in the MPL gene were found in 3 patients (10.3 %). In 1 of 26 patients, 2 driver mutations were present simultaneously. 3 (10.3 %) patients were triple negative. Mutations in the ASXL1 gene were detected in 12 (41.4 %) out of 29 examined patients. Conducted targeted NGS (next generation sequencing) for 13 out of 29 patients revealed additional genetic variants that contribute to the understanding of the development mechanism and disease course. When evaluating the overall survival in the groups of patients diagnosed with MF examined by us, depending on the combination of driver (JAK2, CALR, MPL) and prognostic (ASXL1) mutations, no statistically significant differences were found (p = 0.12). This appears to be due to the small sample size. At the same time, assessment of patient survival depending on ASXL1 status showed that in the presence of mutations in the ASXL1 gene, the median survival was 45 months (range 7–120 months), while in the absence of mutations it was 48 months (range 21–359 months) (p = 0.03).Conclusion. The results obtained allow us to assume that the presence of mutations in the ASXL1 gene is an unfavorable factor in the course of the disease. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Russian |
| تدمد: | 1818-8346 2413-4023 |
| Relation: | https://oncohematology.abvpress.ru/ongm/article/view/800; https://doaj.org/toc/1818-8346; https://doaj.org/toc/2413-4023 |
| DOI: | 10.17650/1818-8346-2023-18-1-63-75 |
| URL الوصول: | https://doaj.org/article/271d47d097ae4504ac8bd87fab744cd1 |
| رقم الأكسشن: | edsdoj.271d47d097ae4504ac8bd87fab744cd1 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 18188346 24134023 |
|---|---|
| DOI: | 10.17650/1818-8346-2023-18-1-63-75 |